Entrada Therapeutics, Inc. 2026: Revenue $898K, EPS ($1.01) — 10-Q Summary
I'm LongbridgeAI, I can summarize articles.Entrada Therapeutics reported Q2 2026 results with $898K collaboration revenue, a net loss of $42.76M, and diluted EPS of ($1.01). Clinical programs for DMD are advancing, with safety endpoints met in Cohort 1. The Vertex partnership on VX-670 is progressing, with results expected in H2 2026. The company holds $223M in cash, sufficient to fund operations through Q3 2027.
Entrada Therapeutics, Inc. reported second-quarter 2026 results in its 10-Q showing collaboration revenue of $898K, a net loss of ($42.76M) and diluted loss per share of ($1.01), compared with $1.95M revenue, a ($43.1M) net loss and ($1.04) diluted loss per share in the prior-year quarter.
Financial Highlights
| Metric | Current quarter | Prior year quarter | YoY change |
| Revenue¹ | $898K | $1.95M | (53.9%) |
| Net income² | ($42.76M) | ($43.1M) | 0.8% |
| Diluted EPS³ | ($1.01) | ($1.04) | 2.9% |
¹ Reported as “Collaboration revenue”. ² Reported as “Net loss”. ³ Reported as “loss per share, basic and diluted”.
Business Highlights
- Clinical advancement across multiple DMD programs (ELEVATE-44/45/50/51): Cohort 1 (6 mg/kg) completed and met safety endpoints with statistically significant functional improvements correlated with increased dystrophin; additional cohorts and open-label extensions are ongoing with planned readouts through 2027.
- Partnerships and pipeline: Collaboration with Vertex on VX-670 progressing with MAD dosing; results expected in H2 2026. Ocular program ENTR-801 selected, with a second ocular candidate planned for H2 2026.
- Liquidity and operations: Cash resources of $223M as of June 30, 2026 are expected to fund operations into Q3 2027; R&D spending is focused on clinical execution and manufacturing scale-up.
Original SEC Filing: Entrada Therapeutics, Inc. [ TRDA ] - 10-Q - Aug. 05, 2026